1. Pfisterer M, Brunner-La Rocca HP, Buser PT et al. BASKET-LATE Investigators. Late clinical events after clopidogrel discontinuation may limit the benefit of drug-eluting stents: an observational study of drug-eluting versus bare-metal stents. J Am Coll Cardiol. 2006; 48(12): 2584–9.
2. Camenzind E, Steg PG, Wijns W. A meta-analysis of first generation drug eluting stent programs. Circulation 2007; 115: 1440–5.
3. Cutlip DE, Windecker S, Mehran R et al. Clinical end points in coronary stent trials: a case for standardized definitions. Circulation 2007; 115: 2344–51.
4. Werkum, JW, de Korte FI, Heestermans AA et al. High recurrence rates after a first episode of stent thrombosis: Results from the Dutch Stent Thrombosis Study. American College of Cardiology Scientific Sessions/i2 Summit-SCAI Annual Meeting; March 29, 2008; Chicago, IL.
5. Nakazawa G, Finn AV, Virmani R. Drug-eluting stent pathology-should we still be cautious? Nat Clin Pract Cardiovasc Med 2008; 5(1): 1–3.
6. Awata M, Kotani J, Uematsu M. Serial angioscopic evidence of incomplete neointimal coverage after sirolimus-eluting stent implantation: comparison with bare-metal stents. Circulation 2007; 116(8): 910–6.
7. Togni M, Ra..ber L, Cocchia R et al. Local vascular dysfunction after coronary paclitaxel-eluting stent implantation. Int J Cardiol 2007; 120(2): 212–20.
8. Virmani R, Guagliumi G, Farb A et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701–5.
9. Nebeker JR, Virmani R, Bennett CL et al. Hypersensitivity cases associated with drug-eluting coronary stents: a review of available cases from the Research on Adverse Drug Events and Reports (RADAR) project. J Am Coll Cardiol. 2006; 47(1): 175–81.
10. Zhang F, Qian J, Ge J. Very late stent thrombosis in late stent malapposition after sirolimus-eluting stent implantation. Int Heart J. 2007; 48(5): 591–6.
11. Steffel J, Latini RA, Akhmedov A. Rapamycin, but not FK-506, increases endothelial tissue factor expression: implications for drug-eluting stent design. Circulation. 2005; 112(13): 2002–11.
12. Stone GW, Moses JW, Ellis SG et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007; 356: 998–1008.
13. Spaulding C, Daemen J, Boersma E et al. A pooled analysis of data comparing sirolimus-eluting stents with bare-metal stents. N Engl J Med 2007; 356: 989–97.
14. Mauri L, Hsieh WH, Massaro JM et al. Stent thrombosis in randomized clinical trials of drug-eluting stents. N Engl J Med 2007; 356(10): 1020–9.
15. Nordmann AJ, Briel M, Bucher HC. Mortality in randomized controlled trials comparing drug-eluting vs. bare metal stents in coronary artery disease: a meta-analysis. Eur Heart J 2006 Dec; 27(23): 2784–814.
16. Stettler C, Wandel S, Allemann S et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet. 2007; 370(9591): 937–48.
17. Daemen J, Ong AT, Stefanini GG et al. Three-year clinical follow-up of the unrestricted use of sirolimus-eluting stents as part of the Rapamycin-Eluting Stent Evaluated at Rotterdam Cardiology Hospital (RESEARCH) registry. Am J Cardiol. 2006; 98(7): 895–901.
18. de la Torre-Herna´ndez JM, Alfonso F, Herna´ndez F et al. ESTROFA Study Group.Drug-eluting stent thrombosis: results from the multicenter Spanish registry ESTROFA (Estudio ESpan~ol sobre TROmbosis de stents FArmacoactivos). J Am Coll Cardiol 2008; 51(10): 986–90.
19. Tu JV, Bowen J, Chiu M et al. Effectiveness and safety of drug-eluting stents in Ontario. N Engl J Med. 2007; 357(14): 1393–402.
20. Steg G. Patients face more than fourfold higher risk of death than bare-metal-stent-treated patients oral presentation at the European Society of Cardiology Congress 2007.
21. Jensen LO, Maeng M, Kaltoft A et al. Stent thrombosis, myocardial infarction, and death after drug-eluting and bare-metal stent coronary interventions. J Am Coll Cardiol. 2007; 50(5): 463–70.
22. Lagerqvist B, James SK, Stenestrand U et al. Long-term outcomes with drug-eluting stents versus bare-metal stents in Sweden. N Engl J Med 2007; 356: 1009–19.
23. Williams DO, Abbott JD, Kip KE. DEScover Investigators.Outcomes of 6906 patients undergoing percutaneous coronary intervention in the era of drug-eluting stents: report of the DEScover Registry. Circulation. 2006; 114(20): 2154–62.
24. Abbott JD, Voss MR, Nakamura M et al. Unrestricted use of drug-eluting stents compared with bare-metal stents in routine clinical practice: findings from the National Heart, Lung, and Blood Institute Dynamic Registry. J Am Coll Cardiol 2007; 50(21): 2029–36.
25. Абугов С.А., Саакян Ю.М., Поляков Р.С., Билич А.Г. Клиническая эффективность и безопасность коронарной ангиопластики с использованием стентов с лекарственным покрытием: результаты 5-летнего наблюдения. Consilium Medicum. 2009; 11(10).
26. Бокерия Л.А., Алекян Б.Г., Голухова Е.З. и др. Применение стентов с лекарственным антипролиферативным покрытием в лечении больных ишемической болезнью сердца. Креативн. кардиол. 2007; 1–2.
27. Беленков Ю.Н., Матчин Ю.Г., Горгадзе Т.Г. и др. Применение сиролимуспокрытых стентов «Cypher» у больных ИБС с различными типами поражения коронарных артерий. Consilium Medicum. 2006; 8(11).
28. Mauri L, Silbaugh TS, Wolf RE et al. Long-term clinical outcomes after drug-eluting and bare-metal stenting in massachusetts. Circulation 2008; 118(18): 1817–27.
29. Shishehbor MH, Goel SS, Kapadia SR et al. Long-term impact of drug-eluting stents versus bare-metal stents on all-cause mortality. J Am Coll Cardiol 2008; 52: 1041–48.
30. Anstrom KJ, Kong DF, Shaw LK et al. Long-term clinical outcomes following coronary stenting. Arch Intern Med 2008; 168: 1647–55.
31. Буза В.В., Карпов Ю.А., Самко А.Н. и др. Оценка течения ишемической болезни сердца после установки стентов с лекарственным покрытием и непокрытых металлических стентов: данные трехлетнего наблюдения. Кардиология. 2009; 1: 9–13.

Ю.А.Карпов, А.Н.Самко, В.В.Буза